Arrowhead Pharmaceuticals(ARWR)2024-11-26 21:19Financial Performance - Arrowhead Pharmaceuticals reported a revenue of 240.735 million in the previous year, representing a decline of approximately 98.5%[11] - The company incurred a net loss attributable to Arrowhead Pharmaceuticals of 205.275 million in the prior year, indicating an increase in losses of about 192%[11] - Arrowhead's total cash resources increased to 403.626 million in 2023, reflecting a growth of approximately 68.7%[11] Collaborations and Agreements - Arrowhead strengthened its balance sheet through a licensing and collaboration agreement with Sarepta Therapeutics, which will provide 500 million in cash and 10 billion in potential milestone payments from the collaboration with Sarepta Therapeutics, in addition to royalties on commercial sales[3] Product Development - The company submitted its first New Drug Application (NDA) to the U.S. FDA for investigational plozasiran, aiming for a potential commercial launch in 2025, pending FDA approval[4] - Plozasiran demonstrated mean reductions in triglycerides of up to 73% in patients from the MUIR study and 86% in patients from the SHASTA-2 study, with favorable reductions in remnant cholesterol and non-HDL cholesterol[5] - The company initiated pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridemia[6] Manufacturing and Operations - Arrowhead's manufacturing facility in Verona, WI, successfully completed requirements to manufacture GMP drug substance, enabling support for clinical trials in the U.S. and abroad[7] Community Engagement - The company launched a new disease awareness campaign, 'We'll Get There Soon,' aimed at the rare disease community affected by familial chylomicronemia syndrome[7]